STOCK TITAN

Eyeonix AIQ proposes 30.6M-share software acquisition

Under the proposal, Eyeonix MedAIQ would assume responsibility for ongoing development, while Eyeonix S.A. would transfer all rights in the asset.

Available on EDGAR Accepted by SEC EDGAR Learn about SEC filing dates
(Moderate)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Form Type
8-K

Rhea-AI Filing Summary

Eyeonix AIQ, Inc. (EAIQ) said its wholly owned subsidiary, Eyeonix MedAIQ, entered into a memorandum of understanding with Eyeonix S.A. regarding the proposed acquisition of COMMAND HEALGRID software source code. As consideration, Eyeonix AIQ would issue 30,600,000 shares of common stock to Eyeonix S.A.

Under the proposal, Eyeonix S.A. would transfer all of its rights in the asset to Eyeonix MedAIQ, which would assume responsibility for ongoing development. The transaction is expected to finalize in this calendar year.

Item 8.01 Other Events Other
Voluntary disclosure of events the company deems important to shareholders but not covered by other items.
Common shares as consideration 30,600,000 shares Proposed consideration payable to Eyeonix S.A. for the COMMAND HEALGRID asset
MOU date October 30, 2026 Date Eyeonix MedAIQ entered into the MOU with Eyeonix S.A.
Expected transaction timing 2026 calendar year Expected finalization of the proposed transaction
Memorandum of Understanding regulatory
"entered into a Memorandum of Understanding"
A memorandum of understanding (MOU) is a formal agreement between two or more parties that outlines their shared intentions and plans to work together. It acts like a handshake in writing, clarifying each side’s roles and expectations before any official contract is signed. For investors, an MOU signals that parties are serious about collaboration, which can influence future business opportunities and potential growth.
source code technical
"source code for the software known as COMMAND HEALGRID"
forward-looking statements regulatory
"Forward-looking statements about the proposed transaction"
Forward-looking statements are predictions or plans that companies share about what they expect to happen in the future, like estimating sales or profits. They matter because they help investors understand a company's outlook, but since they are based on guesses and assumptions, they can sometimes be wrong.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many EAIQ shares are proposed as consideration for COMMAND HEALGRID?

Eyeonix AIQ would issue 30,600,000 shares of common stock to Eyeonix S.A. as consideration for the proposed transfer of all rights in COMMAND HEALGRID.

When is the EAIQ COMMAND HEALGRID transaction expected to finalize?

The transaction is expected to finalize in this calendar year.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
false 0001807689 0001807689 2026-11-03 2026-11-03 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934

November 3, 2026

Date of Report (Date of earliest event reported)

EYEONIX AIQ, INC. (EAIQ)

(Exact name of registrant as specified in its charter)

WY 000-54457 83-4100110
(State or other jurisdiction of
incorporation)
(Commission File Number) (IRS Employer Identification No.)

 

30 N Gould Street #60224, Sheridan, WY 82801
(Address of principal executive offices) (Zip Code)

 

(727) 692-3348

Registrant’s telephone number, including area code

N/A

(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class Trading Symbol(s) Name of each exchange
on which registered
N/A N/A N/A

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☑

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

Section 1 – Registrants Business and Operations

Item 8.01 Other Events.

 

On October 30, 2026, Eyeonix MedAIQ, Inc., a Wyoming corporation and wholly owned subsidiary of Eyeonix AIQ, Inc. (the “Company”), entered into a Memorandum of Understanding (the “MOU”) with Eyeonix S.A., a company organized under the laws of Greece (“Eyeonix Greece”), regarding the proposed acquisition of the source code for the software known as COMMAND HEALGRID (the “Asset”), which was developed by Eyeonix Greece.

 

Under the proposed transaction, Eyeonix Greece would transfer to Eyeonix MedAIQ all of its rights in the Asset, and Eyeonix MedAIQ would assume responsibility for the Asset’s ongoing development. As consideration, the Company would issue to Eyeonix Greece 30,600,000 shares of its common stock.

 

The transaction is expected to finalize in this calendar year.

 

Forward-looking statements. This report contains forward-looking statements about the proposed transaction, including its terms, timing and completion. These statements involve risks and uncertainties, and actual results may differ materially. The Company undertakes no obligation to update them except as required by law.

 

 

 

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  EYEONIX AIQ, INC.  
  (Registrant)  
       
Date: 11/03/2026 By: /s/ George Athanasiadis  
  Name: George Athanasiadis  
  Title: CEO/Director  

 

Filing Exhibits & Attachments

3 documents

Keep reading